{"id":3684,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/amitriptyline-hydrochloride-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"amitriptyline-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/amitriptyline-hydrochloride-txt\/","title":{"rendered":"Amitriptyline hydrochloride.txt"},"content":{"rendered":"

Amitriptyline hydrochloride<\/h1>\n

CLINICAL USE <\/H3>
\nTricyclic antidepressant:<\/p>\n
  • Depression, used especially where\n

    sedation is required<\/p>\n

  • Neuropathic pain\n

    DOSE IN NORMAL RENAL FUNCTION <\/H3>
    \n10\u2013200 mg daily depending on indication
    \n

    PHARMACOKINETICS <\/H3>
    \n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n313.9\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n96\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \n<2\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \n6\u201336\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \n9\u201325\/Unchanged
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
    \n
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nDose as in normal renal function
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nNot dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nNot dialysed. Dose as in normal renal function
    \n
  • HDF\/high flux &nbsp :
    \nUnknown dialysability. Dose as in
    \nnormal renal function
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nNot dialysed. Dose as in normal renal function
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs
    \nAlcohol: increased sedative effect<\/p>\n
  • Analgesics: increased risk of CNS toxicity\n

    with tramadol; possibly increased risk
    \nof side effects with nefopam; possibly
    \nincreased sedative effects with opioids<\/p>\n

  • Antiarrhythmics: increased risk of\n

    ventricular arrhythmias with amiodarone
    \n\u2013 avoid concomitant use; increased risk
    \nof ventricular arrhythmias with drugs that
    \nprolong the QT interval; increased risk of
    \narrhythmias with propafenone<\/p>\n

  • Antibacterials: increased risk of\n

    ventricular arrhythmias with moxifloxacin
    \n\u2013 avoid concomitant use; concentration
    \npossibly reduced by rifampicin<\/p>\n

  • Anticoagulants: may alter anticoagulant\n

    effect of coumarins<\/p>\n

  • Antidepressants: possibly increased\n

    serotonergic effects with duloxetine;
    \nenhanced CNS excitation and
    \nhypertension with MAOIs and
    \nmoclobemide; concentration possibly
    \nincreased with SSRIs; concentration
    \nreduced by St John\u2019s wort<\/p>\n

  • Anti-epileptics: convulsive threshold\n

    lowered; concentration reduced by
    \ncarbamazepine, primidone, barbiturates
    \nand possibly phenytoin<\/p>\n

  • Antimalarials: avoid concomitant use with\n

    artemether\/lumefantrine
    \nAntipsychotics: increased risk of <\/p>\n

    ventricular arrhythmias especially with
    \npimozide; increased antimuscarinic
    \neffects with clozapine and phenothiazines;
    \nconcentration increased by antipsychotics<\/p>\n

  • Antivirals: increased tricyclic side effects\n

    with amprenavir; concentration possibly
    \nincreased with ritonavir
    \nAtomoxetine: increased risk of ventricular <\/p>\n

    arrhythmias and possibly convulsions
    \nBeta-blockers: increased risk of ventricular <\/p>\n

    arrhythmias with sotalol<\/p>\n

  • Clonidine: tricyclics antagonise\n

    hypotensive effect; increased risk of
    \nhypertension on clonidine withdrawal<\/p>\n

  • Dopaminergics: avoid use with\n

    entacapone; CNS toxicity reported with
    \nselegiline and rasagiline<\/p>\n

  • Pentamidine: increased risk of ventricular\n

    arrhythmias<\/p>\n

  • Sibutramine: increased risk of CNS\n

    toxicity \u2013 avoid concomitant use. <\/p>\n

  • Sympathomimetics: increased risk of\n

    hypertension and arrhythmias with
    \nadrenaline and noradrenaline; metabolism
    \npossibly inhibited by methylphenidate<\/p>\n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4>
    \n\u2013
    \n

    Route <\/H4>
    \nOral<\/p>\n

    Rate of Administration <\/H4>
    \n\u2013
    \n

    Comments<\/H4>
    \n\u2013
    \n

    OTHER INFORMATION <\/H4><\/p>\n
  • Introduce treatment gradually in renal\n

    impairment due to dizziness and postural
    \nhypotension<\/p>\n

  • Withdraw treatment gradually\n
  • Anticholinergic side effects: causes urinary\n

    retention, drowsiness, dry mouth, blurred
    \nvision and constipation<\/p>\n","protected":false},"excerpt":{"rendered":"

    Amitriptyline hydrochloride CLINICAL USE Tricyclic antidepressant: Depression, used especially where<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3684","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3684"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3684\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}